As landmark Ferring & Seres Therapeutics approvals prove the safety of the microbiome modality, robust clinical efficacy data for disease beyond infectious is now paramount to reinvigorate investment across the community.

The 9th Microbiome Movement Drug Development Summit returns as the industry’s trusted, definitive forum for the global network of microbial therapeutic developers. It ensures teams can stay ahead of the curve to robustly prove clinical efficacy as regulator and investor scrutiny necessitates more compelling data than ever before.

We are proud to be a part of this year’s speaker faculty, and bring insights you can help to strategize! Align your pipeline strategy with key industry leaders in the US and across the globe where investment and collaborations are shaping the future of microbiome drug development. Find Beacon’s Ada Lam’s, Research Analyst, full presentation synopsis and presentation details here!